Frontiers of cancer care in Asia-Pacific region: cancer care in Australia

ES Koh*1, MBBS, FRANZCR, VT Do2, MBBS, FRANZCR, MB Barton1, MBBS, FRANZCR

1 Collaboration for Cancer Outcomes Research and Evaluation (CCORE) University of New South Wales, Liverpool Hospital, Liverpool, New South Wales, Australia
2 Department of Radiation Oncology, Westmead hospital, Wentworthville, New South Wales, Australia

Received 14 May 2008; accepted 31 May 2008

ABSTRACT

Cancer has a significant impact on the Australian community. One in three men and one in four women will develop cancer by the age of 75. The estimated annual health expenditure due to cancer in 2000-1 in Australia was $2.7 billion, representing 5.5% of the country’s total healthcare expenditure. An historical overview of the national cancer control strategies in Australia is provided. In males, the five most common cancers in order of decreasing incidence are: prostate cancer, colorectal cancer, lung cancer, melanoma and lymphoma, while for Australian women, breast cancer is the most common cancer. Key epidemiologic information about these common cancers, current management issues and comprehensive national clinical practice guidelines (where available) are highlighted. Aspects of skin cancer, a particularly common cancer in the Australian environment – with a focus on melanoma – are also included.

Cancer outcomes in Australia, measured by selected outcomes, are among the best in the world. However, there is still evidence of health inequalities, especially among patients residing in regional and remote areas, the indigenous population and people from lower socio-economic classes. Limitations of current cancer care practices in Australia, including provision of oncology services, resources and other access issues, as well as suggested improvements for future cancer care, are summarised. Ongoing implementation of national and state cancer control plans and evaluation of their effectiveness will be needed to pursue the goal of optimal cancer care in Australia. © 2008 Biomedical Imaging and Intervention Journal. All rights reserved.

Keywords: Cancer care Australia, health inequalities and cancer outcomes

OVERVIEW OF CANCERS AND CANCER STATISTICS IN AUSTRALIA

Cancer has a significant impact on the Australian community. One in three men and one in four women will develop cancer by the age of 75. In 2004, there were over 98,000 new cases of cancer (excluding non-melanomatous skin cancer [NMSC]) and over 36,000 deaths attributable to cancer in Australia, in a population...
of just over 20 million people. This represented a 4.7% increase from cases diagnosed in 2003 and a 25.2% increase from 1994 [1]. Both the number of new cases is increasing, as is the number of people living with the diagnosis of cancer [2]. Between 1990 and 2000, there was a 36% increase in new cancer cases, but only a 12% population growth. The annual age-standardised incidence rate is 338 per 100,000 people, with a 1 in 3 risk of developing a cancer before the age of 75 and 1 in 2 by the age of 85 [1].

Cancer is the leading cause of death and the leading cause of loss of Disability Adjusted Life Years. Over 60% of people diagnosed with cancer survive more than five years in Australia, a figure that is second only to the USA. It is estimated that over 247,000 people are living in the Australian community with a cancer diagnosis up to five years earlier (excluding NMSC) [1,3]. The estimated annual health expenditure due to cancer in 2000-1 in Australia was $2.7 billion [4], representing 5.5% of the total healthcare expenditure.

CANCER CONTROL AND HEALTHCARE POLICY IN AUSTRALIA

Australia has a complex healthcare system. The Australian (Federal) Government subsidises out-of-hospital medical services through its Medicare system [5] created as a universal access healthcare system for Australian citizens. The Federal Government also has responsibility for the breast and cervical cancer screening programs, the Pharmaceutical Benefits Scheme (PBS) [6], and other areas of service provision including radiotherapy services and aged care. Hospital care and some community services are the responsibility of State and Territory governments and these are publicly funded, with private services supported by health insurance plans. Cancer care and cancer control have a large component of non-government and non-profit (voluntary) support, the latter notably including Cancer Councils, based in each State and Territory with a national office, and The Cancer Council Australia.

NATIONAL CANCER CONTROL STRATEGIES IN AUSTRALIA – A HISTORICAL OVERVIEW

In 1994 the publication ‘Better Health for Australians’ [7] was released. Cancer was one of the initial health focus areas selected in recognition of its effects on the Australian population and the potential to reduce morbidity and improve quality of life by improving cancer control. Seven priority cancers were selected: breast, cervical, lung, colorectal, melanoma, non-melanomatous skin cancer and prostate cancer. The Australian Cancer Society (now the Cancer Council Australia) conducted a national series of expert workshops and from this produced the ‘National Cancer Prevention Policy for Australia’ [8-10]. Prevention strategies covered tobacco, ultraviolet (UV) radiation, diet, physical activity, overweight and obesity, and alcohol-related issues. This policy [9] also included goals and strategies related to screening for breast, cervical and colorectal cancer. Consensus-based proposed actions were developed subsequently and published in ‘Cancer Control towards 2002’ [9,11].

In 2003, the Optimising Cancer Care in Australia (OCCA) report [2] compiled with key organisations and individuals in the field of cancer care, aimed to identify systematic problems, barriers and failings of the current system of cancer care in Australia. The OCCA report helped stimulate major action in cancer control in Australia at both national and state levels, and is one of the key documents on which the National Service Improvement Framework (NSIF) for Cancer [2,12] is based. The eight priority actions include establishing:

- Integrated and networked cancer services;
- Accreditation for cancer services and credentialing of practitioners;
- Funding structures to support multi-disciplinary care;
- Approaches to monitor cancer control;
- Provision of consumer information about cancer risks, prevention, early detection, diagnosis and treatment, and supportive care;
- Support for primary care providers to provide appropriate assessment of risk;
- Implementation and evaluation of culturally appropriate programs to improve cancer control; and
- Review of gaps in research and opportunities at least every three years.

The strengths, weaknesses and future directions of these initiatives will be discussed in a later section.

Common cancers in Australia

In males, the five most common cancers in order of decreasing incidence are:
1. Prostate cancer
2. Colorectal cancer
3. Lung cancer
4. Melanoma
5. Lymphoma

Tables 1 and 2 outline the incidence and mortality figures for the five most common cancers in Australian males over the period 1996-2004 [1].

In females, the five most common cancers in order of decreasing incidence are:
1. Breast cancer
2. Colorectal cancer
3. Melanoma
4. Lung cancer
5. Lymphoma

Tables 3 and 4 outline the incidence and mortality figures for the five most common cancers in Australian females over the period 1996-2004 [1].

The following section summarises some key epidemiologic information about these common cancers in Australia and highlights current issues and methodologies in management. Where available for
### Table 1
The five most common cancers in Australian males over the period 1996-2004 [4] (Rates are age-standardised to the Australian population and expressed per 100,000 population).

| Cancer site/type                  | 1996  | 1997  | 1998  | 1999  | 2000  | 2001  | 2002  | 2003  | 2004  |
|----------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Prostate                         | 137.6 | 129.8 | 128.1 | 129.5 | 128.2 | 130.3 | 134.4 | 146.8 | 163.4 |
| Colorectal                       | 78.3  | 77.2  | 74.8  | 75.2  | 79.6  | 78.4  | 75.7  | 73.8  | 75.1  |
| Lung, bronchus & trachea         | 69.8  | 69.3  | 67.5  | 65.6  | 63.4  | 62.1  | 60.7  | 58.6  | 61.6  |
| Melanoma of skin                 | 53.8  | 56.0  | 52.3  | 54.2  | 54.7  | 55.5  | 59.9  | 58.1  | 56.6  |
| Lymphoma                         | 23.9  | 23.4  | 22.9  | 23.6  | 24.1  | 23.8  | 24.6  | 24.4  | 24.3  |
| All cancers                      | 563.0 | 553.2 | 544.0 | 545.4 | 544.8 | 548.7 | 553.6 | 556.7 | 573.4 |

Notes:
1. Non-melanoma skin cancer (NMSC, ICD-10 code C44), known to be the most common cancer type, is excluded from this list because basal cell carcinoma and squamous cell carcinoma, the two most common types of NMSC, are not notifiable cancers.
2. Rates are age-standardised to the Australian population at 30 June 2001 and expressed per 100,000 population.
3. Source of data: National Cancer Statistics Clearing House, AIHW.

### Table 2
Mortality figures from 2004 for Australian males for the five most common cancers (Rates are age-standardised to the Australian population and expressed per 100,000 population) [4]

| Cancer site/type                  | New cases | Deaths |
|----------------------------------|-----------|--------|
|                                 | Number   | % of total | Rate | Risk  | Number   | % of total | Rate | PYLL  |
| Prostate                         | 15,759   | 28.7     | 163.4 | 1 in 5 | 2,792   | 12.9     | 33.0  | 6,193 |
| Colorectal                       | 7,160    | 13.0     | 75.1  | 1 in 10| 2,196   | 10.1     | 23.8  | 14,483|
| Lung, bronchus & trachea         | 5,826    | 10.6     | 61.6  | 1 in 11| 4,733   | 21.8     | 50.8  | 28,190|
| Melanoma of skin                 | 5,503    | 10.0     | 56.6  | 1 in 15| 815     | 3.8      | 8.7   | 8,605 |
| Lymphoma                         | 2,352    | 4.3      | 24.3  | 1 in 33| 803     | 3.7      | 8.8   | 6,513 |
| All cancers                      | 54,870   | 100.0    | 573.4 | 1 in 2 | 21,670  | 100.0    | 237.5 | 295,080|

Notes:
1. Non-melanoma skin cancer (NMSC, ICD-10 code C44), known to be the most common cancer type, is excluded from this list because basal cell carcinoma and squamous cell carcinoma, the two most common types of NMSC, are not notifiable cancers. However, NMSC is included in the data in the mortality columns. In 2004 there were a total of 360 (including 251 male deaths) from NMSC.
2. Rates are age-standardised to the Australian population at 30 June 2001 and expressed per 100,000 population.
3. Risk in 2004 of being diagnosed with a particular cancer before reaching age 85 years.
4. Potential years of life lost (PYLL) between the ages of 0 and 84 years.
5. Sources of data: National Cancer Statistics Clearing House and National Mortality Database, AIHW.
Table 3  The five most common cancers in Australian females over the period 1996-2004. (Rates are age-standardised to the Australian population and expressed per 100,000 population) [4]

| Cancer site/type                  | 1996  | 1997  | 1998  | 1999  | 2000  | 2001  | 2002  | 2003  | 2004  |
|-----------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Breast                            | 109.1 | 111.4 | 114.6 | 111.2 | 115.6 | 117.2 | 117.2 | 112.2 | 112.8 |
| Colorectal                        | 52.3  | 52.5  | 52.0  | 53.8  | 52.7  | 54.5  | 51.8  | 51.5  | 51.5  |
| Melanoma of skin                  | 38.1  | 40.3  | 37.1  | 37.6  | 38.4  | 38.4  | 40.8  | 38.0  | 39.4  |
| Lung, bronchus & trachea          | 26.4  | 27.0  | 26.3  | 26.2  | 27.9  | 28.0  | 28.9  | 27.7  | 29.3  |
| Lymphoma                          | 16.9  | 17.4  | 17.1  | 17.2  | 17.7  | 17.0  | 17.9  | 17.1  | 17.5  |
| All cancers                       | 385.9 | 390.2 | 392.0 | 388.0 | 394.5 | 396.8 | 402.7 | 389.9 | 395.4 |

Notes:
(a) Non-melanoma skin cancer (NMSC, ICD-10 code C44), known to be the most common cancer type, is excluded from this list because basal cell carcinoma and squamous cell carcinoma, the two most common types of NMSC, are not notifiable cancers.
(b) Rates are age-standardised to the Australian population at 30 June 2001 and expressed per 100,000 population.
(c) Source of data: National Cancer Statistics Clearing House, AIHW.

Table 4  Mortality figures from 2004 for Australian females for the five most common cancers. (Rates are age-standardised to the Australian population and expressed per 100,000 population) [4]

| Cancer site/type                  | New cases | Deaths |
|-----------------------------------|-----------|--------|
|                                   | Number    | % of total | Rate | Risk | Number | % of total | Rate | PYLL |
| Breast                            | 12,126    | 27.9  | 112.8 | 1 in 9 | 2,664 | 15.8  | 23.8 | 48,910 |
| Colorectal                        | 5,817     | 13.4  | 51.5  | 1 in 14 | 1,872 | 11.1  | 16.0 | 21,798 |
| Melanoma of skin                  | 4,219     | 9.7   | 39.4  | 1 in 24 | 385   | 2.3   | 3.4  | 6,790  |
| Lung, bronchus & trachea          | 3,270     | 7.5   | 29.3  | 1 in 24 | 2,526 | 15.0  | 22.3 | 34,770 |
| Lymphoma                          | 1,920     | 4.4   | 17.5  | 1 in 46 | 736   | 4.4   | 6.3  | 8,725  |
| All cancers                       | 43,466    | 100.0 | 395.4 | 1 in 3  | 16,819| 100.0 | 145.8| 229,483|

Notes:
(a) Non-melanoma skin cancer (NMSC, ICD-10 code C44), known to be the most common cancer type, is excluded from this list because basal cell carcinoma and squamous cell carcinoma, the two most common types of NMSC, are not notifiable cancers. However, NMSC is included in the data in the mortality columns. In 2004 there were a total of 360 (including 109 female deaths) from NMSC.
(b) Rates are age-standardised to the Australian population at 30 June 2001 and expressed per 100,000 population.
(c) Source of data: National Cancer Statistics Clearing House and National Mortality Database, AIHW.
relevant cancers, national clinical practice guidelines are referenced.

SKIN CANCER – A COMMON CANCER IN THE AUSTRALIAN ENVIRONMENT

Melanoma and non-melanomatous skin cancer

The ultraviolet (UV) light in sunlight damages the DNA in skin, causing skin cells to mutate and contribute to the process of carcinogenesis. Humans have evolved a protective mechanism for filtering out UV light from specialised skin cells (melanocytes), which produce a dark pigment called melanin that absorbs UV light and prevents its damaging effects [13, 14]. The mass migration of peoples in the 19th and 20th centuries redistributed populations with low melanin protection to high UV regions. For example, when fair-skinned Anglo-Celts and Europeans migrated to hotter climates such as that in Australia, the rates of skin cancer increased [14]. Australians have the highest documented incidence of skin cancer in the world, and skin cancer is the most common form of cancer in Australia, where the lifetime risk of skin cancer is 1 in 2 people [1]. Those persons most at risk are:

- Persons with fair skin and blue eyes (having the least amount of melanin)
- Persons with significant outdoor sun exposure such as farm or construction workers
- Urban indoor workers who spend weekends or holidays (or their childhood and young adulthood) in the sun.

Melanoma

Australia has the highest incidence and mortality rates for melanoma, as summarised in Table 5 demonstrating international trends [15]. The evidence of a causative link with sunlight exposure is compelling, with severe episodic sunburn in early life correlating best with melanoma risk [15-19]. The Sydney Melanoma Unit (SMU) has been the global pioneer in the diagnosis, staging and management of this malignancy [20-22], especially with regard to multi-disciplinary care [20], and its contribution to the formulation of comprehensive clinical practice guidelines published by the National Health and Medical Research Council (NHMRC) [18]. The SMU has been particularly instrumental in defining the role and technique of sentinel lymph node mapping in melanoma [21,23] and has led international collaborative clinical and translational research trials [24].

Lung cancer

Although lung cancer is only the third highest cancer in terms of incidence, it is the leading cause of cancer death in males and females, as well as the top cause of ‘Person Years of Life Lost’ due to cancer in Australia. More than 8,000 Australians are diagnosed with lung cancer each year, with about 7,000 deaths secondary to the disease each year. One in 30 Australians will develop lung cancer by age 75 [1]. Relative survival following a diagnosis of lung cancer in the Australian states during the 1980s and 1990s (for which data is available) varied in the ranges of 10.1-11.1% in males and 12.3%-13.7% in females at five years. More recent Australian data for the period 1992-97 show a five-year relative survival of 11% for males and 14% for females. Comparative international trends in lung cancer are outlined in Table 6. Lung cancer incidence is decreasing in males but increasing in females, with cigarette smoking the major cause in up to 90% of cases. In 2003, there were an estimated 10,378 new cases of all cancers and 7,727 deaths from all cancers in Australia attributed to smoking (see below) [1]. Other causes of lung cancer include environmental (passive) smoking (although the risk is less than active smoking), and occupational exposure to asbestos.

Management issues in lung cancer

In 2004 the NHMRC published clinical practice guidelines for the prevention, diagnosis and management of lung cancer [25]. The primary reason for the publication of these guidelines was to assist in educating and improving the practice and quality of care provided by practitioners who manage lung cancer patients in Australia. The overall aim of the guidelines was thus to improve consistency of care and patient outcomes. These guidelines underscore the value and importance of multi-disciplinary care, as have publications from other Australian centres [26,27]. To date, no national screening program for lung cancer exists in Australia, based on lack of high-level evidence to support its implementation and use [25]. The NHMRC guidelines contain comprehensive evidence-based recommendations regarding the management of both non-small cell lung cancer and small cell lung cancer by stage [25]. Despite the publication and dissemination of these guidelines, however, there is ongoing evidence of practice variation across Australia. For example, in a survey of 24 radiotherapy departments across the country, there was considerable variation in radiotherapy prescription doses for both radical and palliative treatments, immobilisation techniques, and CT planning-based protocols [28]. Data such as this demonstrate the ongoing need for continued assessment of guideline implementation and also updates as new evidence becomes available.

Smoking

Cigarette smoking remains the largest single preventable cause of death and disease including lung cancer. Consequently, tobacco control measures, including taxation and price policies, advertising restrictions, public information, health promotion and smoking cessation support, are pivotal in reducing the burden of disease from smoking. In 2004 the Ministerial Council on Drug Strategy [29] endorsed an action plan under the National Drug Strategic Framework, The National Tobacco Strategy (NTS), 2004-2009 [30]. The
Table 5  Melanoma statistics in four countries [1,4,5,79,80]

|                      | Age-standardised incidence (100,000/year) | Age-standardised mortality (100,000/year) | Lifetime risk (incidence) | Incidence trend over 10 years | Mortality trend over 10 years | Most common cancers (ranking) |
|----------------------|------------------------------------------|------------------------------------------|---------------------------|------------------------------|------------------------------|-------------------------------|
| **Australia (2001) [1]** |                                          |                                          |                           |                              |                              |                               |
| Men                  | 41·4 (world)                             | 5·1 (world)                             | 1 in 25                   | 22% increase                 | 2% increase                  | 4th                           |
| Women                | 31·1 (world)                             | 2·6 (world)                             | 1 in 35                   | 12% increase                 | 0% increase                  | 3rd                           |
| **USA (2001) [4,5]**  |                                          |                                          |                           |                              |                              |                               |
| Men                  | 21·4 (world)                             | 3·9 (world)                             | 1 in 53                   | 31% increase                 | 0% increase                  | 5th                           |
| Women                | 13·8 (world)                             | 1·8 (world)                             | 1 in 78                   | 25% increase                 | 1% decrease                  | 7th                           |
| **The Netherlands (1998) [79]** |                                         |                                          |                           |                              |                              |                               |
| Men                  | 11·5 (Europe)                            | 3·1 (Europe)                            | ..                        | 21% increase                 | 24% increase                 | ..                             |
| Women                | 14·8 (Europe)                            | 2·1 (Europe)                            | ..                        | 11% increase                 | 5% increase                  | ..                             |
| **UK (2000) [80]**   |                                          |                                          |                           |                              |                              |                               |
| Men                  | 9·7 (world)                              | 2·7 (world)                             | 1 in 147                  | 59% increase                 | 20% increase                 | 12th                          |
| Women                | 11·2 (world)                             | 1·9 (world)                             | 1 in 117                  | 41% increase                 | 3% increase                  | 7th                           |

Table 6  Five-year relative survival from lung cancer – international comparisons [3, 48, 81-84].

| Males            | Time period | Age Group | 1 yr (%) | 2 yr (%) | 3 yr (%) | 4 yr (%) | 5 yr (%) |
|------------------|-------------|-----------|----------|----------|----------|----------|----------|
| Australia        | 1992-97     | All       | 34.6     | -        | -        | -        | 11.0     |
| New South Wales  | 1980-94     | 15-89     | 34.0     | 18.0     | 13.4     | 11.2     | 10.1     |
| Europe           | 1985-89     | 15+       | 32.0     | -        | 12.0     | 1.0      | 10.0     |
| United States (SEER) | 1991   | All       | 38.9     | 21.9     | 17.0     | 14.0     | 12.4     |

| Females          | Time period | Age Group | 1 yr (%) | 2 yr (%) | 3 yr (%) | 4 yr (%) | 5 yr (%) |
|------------------|-------------|-----------|----------|----------|----------|----------|----------|
| Australia        | 1992-97     | All       | 37.6     | -        | -        | -        | 14.0     |
| New South Wales  | 1980-94     | 15-89     | 37.3     | 20.8     | 15.9     | 13.5     | 12.3     |
| Europe           | 1985-89     | 15+       | 29.0     | -        | 13.0     | -        | 11.0     |
| United States (SEER) | 1991   | All       | 44.9     | 27.0     | 21.4     | 18.8     | 16.4     |

Notes:
(a)  When comparing survival and mortality data it should be noted that the denominator for survival is the population of patients with disease, whereas the denominator for the mortality rate from lung cancer is the whole population. Thus, the mortality rate may be low is there are a small number of cases with the disease, whereas poor survival results from patients with the disease dying relatively quickly.
Australian government reiterated its determination to reduce tobacco use by ratifying the World Health Organization’s Framework Convention on Tobacco Control [31].

Colorectal cancer

Colorectal cancer (CRC) is the second most common cause of death from cancer, after lung cancer. There are about 11,300 new cases and 4,600 deaths from bowel cancer each year in Australia. The lifetime risk of developing bowel cancer is approximately 1 in 18 Australian men, and 1 in 26 women [1]. Risk factors for the development of CRC include increasing age, low fibre diet, history of polyps and/or colitis, and family history of colorectal cancer.

Population-based bowel screening was tested in a national Pilot Program from November 2002 to June 2004. The National Bowel Cancer Screening Program [32] commenced a phased implementation in August 2006. Initially, screening will be offered to those involved in the Pilot Program and Australians turning 55 or 65 years of age between May 1, 2006 and June 30, 2008. Eligible participants will receive an invitation to complete a faecal occult blood test (FOBT). Those returning a positive FOBT result will be advised to discuss it with their family practitioner, who will generally refer them for further investigations, which will usually be a colonoscopy.

Management issues in colorectal cancer

In 1999, NHMRC released the ‘Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer’ [33], with the second edition released in 2005 [34]. The guidelines are intended to provide a resource for all medical practitioners and health workers who require sound information directed toward the management of patients with colorectal cancer. These guidelines are wide-ranging in scope and provide information which covers prevention and screening, diagnosis and psychosocial matters, as well as the clinical aspects of surgery, radiotherapy and chemotherapy. These guidelines have been well adopted, used with demonstrated concordance and implemented into clinical practice [35]. Another significant change in the management paradigm in CRC has been the patterns of follow-up care. In the past, intensive follow-up after treatment was not as strongly promoted. However, it has now been shown that intensive follow-up leads to earlier detection of recurrence. A Cochrane Review demonstrated that it also improves survival [36].

Breast cancer

Breast cancer is the highest cause of cancer-related deaths among Australian women. The age-standardised incidence of breast cancer in females has increased from 80 per 100,000 population in 1983 to 117 per 100,000 population in 2002. It is projected that there will be 13,261 new cases in 2006 and 14,800 in 2011 in Australia. The lifetime risk of developing breast cancer is approximately 1 in 11 women in Australia. In 2002 there were approximately 114,000 women alive with a past diagnosis of breast cancer [37]. There are various risk factors related to the development of this malignancy, including increasing age, hormonal factors, nulliparity, exogenous oestrogen, a positive family history in first-degree relatives, and previous history of breast cancer or benign breast disease [38].

Management issues in breast cancer

The National Breast and Ovarian Cancer Centre (NBOCC) [39] is Australia’s main body for breast and ovarian cancer control, originally established in 1995 by the Australian government. The NBOCC has produced a spectrum of publications and resources including comprehensive evidence-based clinical practice guidelines relating to all aspects of breast cancer and its management. These aspects include screening and early detection, the management of early, advanced, and metastatic breast cancer [38], radiotherapy and breast cancer, the psychosocial care of adults with cancer, and multi-disciplinary cancer care [39].

The BreastScreen Australia public mammography screening program [40] commenced in most Australian states in 1991. Increased cancer incidence rates were seen in the targeted age groups between 50 and 69, and were greatest in the 60-64 age group. The incidence rates increased from 216 per 100,000 population in 1992 to 334 per 100,000 population in 2002. Table 7 demonstrates a global ranking of incidence and mortality for breast cancer in females with data from selected countries [3, 41].

Prostate cancer

In Australia, prostate cancer is the second most common type of cancer in men (after skin cancer). Relatively little is known about the aetiology of prostate cancer in some men. It is a disease of older men, being rare under the age of 50. When it occurs in men under 50, it is more likely in a man with a family history of prostate cancer. Australians may be more prone to develop prostate cancer as it has been found to be associated with certain diets – including those high in animal fats, low in plant food, and possibly low in certain elements, antioxidants and vitamins – as well as occupational exposure to certain substances, including cadmium and rubber [42].

While variations on the risk strata exist, for the purpose of this review, the American Urological Association (AUA) scheme is referenced, as follows [43]:

- **Low risk**: PSA ≤ 10ng/ml, Gleason score ≤ 6 and clinical stage T1C or T2A
- **Intermediate risk**: PSA > 10ng/ml to 20ng/ml or a Gleason score of 7 or clinical stage T2B
- **High risk**: PSA > 20ng/ml or a Gleason score of 8 to 10 or clinical stage ≥ T2C
Table 7  Global ranking of incidence and mortality for breast cancer in females, selected countries, 2002
GLOBOCAN. (Rates expressed per 100,000 populations and age-standardised to the year 2002
Standard Population of country and to World Standard Population (ASR (W)) [3].

| Population (Female)           | Incidence |           | Mortality |           |
|------------------------------|-----------|-----------|-----------|-----------|
|                              | Numbers   | Crude     | ASR (W)   | Numbers   | Crude     | ASR (W)   |
| World                        | 1,151,298 | 37.4      | 37.4      | 410,712   | 13.3      | 13.2      |
| More Developed Countries     | 636,128   | 103.7     | 67.8      | 189,765   | 30.9      | 18.1      |
| Less Developed Countries     | 514,072   | 20.9      | 23.8      | 220,648   | 9.0       | 10.3      |
| Australia                    | 11,176    | 114.1     | 83.2      | 2,667     | 27.2      | 18.4      |
| Canada                       | 19,540    | 124.0     | 84.3      | 5,305     | 33.7      | 21.1      |
| New Zealand                  | 2,330     | 120.0     | 91.9      | 670       | 34.5      | 24.5      |
| United Kingdom               | 40,298    | 135.5     | 87.2      | 13,303    | 44.0      | 24.3      |
| United States of America     | 209,995   | 143.8     | 101.1     | 42,913    | 29.4      | 19.0      |
| Central and Eastern Europe   | 100,262   | 63.4      | 42.6      | 45,310    | 26.7      | 17.9      |
| Northern Europe              | 62,425    | 128.8     | 82.5      | 19,789    | 40.8      | 22.6      |
| South-Eastern Asia           | 58,495    | 21.8      | 25.5      | 26,818    | 10.0      | 11.8      |
| Southern Europe              | 72,458    | 97.8      | 62.4      | 24,617    | 33.2      | 18.1      |
| Western Europe               | 125,604   | 134.3     | 84.5      | 39,297    | 42.0      | 22.3      |

Notes:
1. Cancer numbers and rates are estimates for the middle of 2002, from the most recent data available, generally 3-5 years earlier.
2. Rates are expressed per 100,000 populations and age-standardised to the year 2002 Standard Population of the corresponding country and to the World Standard Population (ASR (W)).
3. The Age-Standardized Rate (ASR, world standard) is calculated using the 5 age-groups 0-14,15-44,45-54,55-64,65+ years.

Table 8  Breast cancer in females: age-standardised rate and five-year relative survival proportions by region and socioeconomic status, Queensland, 1996-2002. [45].

| Characteristic | Incidence (Average number of cases per year) | ASR (Age-Standardized Rate) | Five-year relative survival (%) |
|---------------|---------------------------------------------|-----------------------------|--------------------------------|
| Geographic area |                                             |                             |                                |
| Major city    | 1,087                                       | 119.5                       | 86.6                           |
| Inner regional| 575                                         | 120.3                       | 87.0                           |
| Outer regional| 280                                         | 99.9                        | 85.8                           |
| Remote        | 33                                          | 89.5                        | 81.9                           |
| Socio-economic status (SES) |                                 |                             |                                |
| Affluent      | 143                                         | 129.4                       | 88.1                           |
| Middle 80% SES| 1,716                                       | 115.5                       | 86.5                           |
| Disadvantaged | 115                                         | 106.2                       | 84.7                           |

Source: Geographical differentials in cancer incidence and survival in Queensland, 1996 to 2002 [45].

Notes:
(a) ASR is the Age-Standardized Rate
(b) Relative survival compares the survival of persons diagnosed with cancer (observed) with that experienced by the same age- and sex-matched population to which they belong (expected). The ratio of observed to expected is used to estimate the proportion of people whose risk of dying has been affected by the disease. This method of analysis does not require knowledge of the cause of death.
**Management issues in prostate cancer**

The National Health and Medical Research Council (NHMRC) is Australia's main body for supporting health and medical research, and for developing health advice for the Australian community, health professionals and governments. In 2002, the NHMRC released the “Clinical practice guideline: Evidence based information and recommendations for the management of localised prostate cancer” [42]. Publication of these evidence-based guidelines has been particularly important in outlining management options and controversies, when weighing up potential treatment-related benefits with relevant morbidities.

**Localized low- to intermediate- risk prostate cancer**

Options for the management of localised prostate cancer include radical prostatectomy, radiotherapy and active surveillance. Radiotherapy includes external beam and interstitial radiotherapy (brachytherapy) treatments. These interventions are options for the treatment of localised prostate cancer because the data currently available in the literature does not provide sufficient clear-cut evidence to indicate the unquestioned superiority of any one form of treatment [42].

**Localised high-risk prostate cancer**

Although active surveillance, non-nerve sparing prostatectomy, high-dose rate brachytherapy and high-dose external beam radiotherapy remain options for the management of patients with high-risk localised disease, recurrence rates are also high. Based on results of randomised controlled trials, the use of hormone therapy in combination with conventional radiotherapy may prolong survival [43].

**Hormone-refractory prostate cancer**

Although hormonal manipulations, such as luteinising hormone-releasing hormone (LHHRH) agonists or castration, are initially effective for 90% of prostate cancer patients, all eventually progress after a median of 18-24 months of treatment to become “androgen-independent” (or hormone-refractory). Upon progression, secondary hormonal manipulations are often employed; however, these treatments are generally less effective, and any anti-cancer effects are usually short-lived. The intravenous chemotherapy agent Docetaxel has been used in the treatment of HRPC and demonstrated a survival benefit in selected patients [44].

**INEQUALITIES IN CANCER SUSCEPTIBILITY AND HEALTH OUTCOMES**

Despite the fact that Australia ranks among the countries with the lowest mortality rates overall, there are defined sub-groups of the population with documented inferior outcomes, particularly women residing in more regional and remote geographic areas (see later section on access issues) [45], those of lower socioeconomic status [41] (see Table 8), and those of indigenous backgrounds [46,47].

**Indigenous Australians**

Indigenous Australians who do not live in the cities are particularly disadvantaged in accessing radiotherapy. Their strong links to place, family and culture mean that travelling to urban centres for radiotherapy is a significant problem. The greater differences in death rates, compared to incidence rates, between indigenous and non-indigenous people could reflect a higher proportion among indigenous people of cancers with high case-fatality rates, a generally more advanced stage of cancer at time of diagnosis, or differences in treatment outcomes by stage of cancer at diagnosis [48]. In a study of 815 indigenous and 810 non-indigenous people living in Queensland and diagnosed with cancer from 1997-2002, the likelihood of death from cancer was 30% higher for indigenous cases than for non-indigenous cases after accounting for cancer stage at diagnosis, treatment, and the higher rates of co-morbidities (such as diabetes, chronic renal disease, respiratory disease and acute coronary conditions) existing among indigenous cases [49]. Analyses of cancer and cancer services for Indigenous people in the Northern Territory have highlighted the fact that the absolute differences in survival after diagnosis with cancer are greatest for cancers with the highest survival in non-indigenous people [46]. A 2004 review concluded that “the experience of indigenous people and cancer provides evidence that the Australian health system is not operating as effectively for indigenous people as for other Australians” and that there was a need for “strengthening primary healthcare services, reducing barriers for access to specialist services and improving collaboration between the two” [46].

**Geographic differences**

There is increasing evidence to suggest that more than half a million Australians who live outside state capital cities [50] are at risk of significantly poorer survival outcomes following a cancer diagnosis, than people with similar diagnoses who reside in major metropolitan areas [51]. People with cancer living in remote and rural areas are diagnosed at a later stage than their city counterparts [52], and moreover, are more likely to die from cancers such as lung, cervix, and uterine malignancies the further they are located from city centres [53]. Specific indicators of reduced access to cancer care services in remote and rural areas include poorer state-of-the-art diagnostic tests, staging and treatment of prostate cancer [54], less breast-conserving surgery [55], and lower probability of completing external beam radiotherapy when referred for treatment of rectal cancer [56]. As recently as 2004, there was ongoing published evidence in the Medical Journal Australia demonstrating that people with cancer residing in regional New South Wales were 35% more likely to
die within five years of diagnosis than patients residing in urban centres [52]. Mortality rates increased with remoteness to cancer facility.

**Geographic differences and socio-economic status (SES)**

In 2006 the AIHW published a comprehensive overview report [41] addressing epidemiologic aspects and clinical outcomes in breast cancer in Australia. The most recent data linking geographic differences and SES come from the state of Queensland (see Table 8). ‘Major city’ and ‘inner regional’ areas had higher five-year survival rates with 86.6% and 87.0% survival respectively, compared with ‘Outer regional’ and ‘Remote’ areas with five-year survival rates of 85.8% and 81.9% survival, respectively, in the 1996-2002 period. Over this same period, ‘Affluent’ areas of Queensland had the highest five-year survival rates with 88.1% compared to ‘Middle 80% SES’ areas with 86.5% survival and the ‘Disadvantaged’ areas with 84.7% five-year relative survival [41].

**ADEQUACY OF FACILITIES AND SERVICES BASED ON THE IDEAL PHILOSOPHY OF CANCER CARE**

This section will address cancer services by specialty type – surgical, medical and radiation oncology, and palliative care services.

**Surgical oncology services**

Surgical expertise tends to be focused on anatomical sites rather than types of pathology. Consequently, individual surgical specialists treat varying proportions of neoplastic and non-neoplastic conditions. A national report is currently being prepared with respect to surgical oncology services, by linking data from Medicare on MBS claims for surgical procedures identified as being primarily cancer-related and also documenting the geographic distribution of these claims.

**Complexity of a surgical oncology intervention, volume of procedures and outcome**

There is increasing evidence that outcome of cancer care, particularly for complex difficult primary surgery, is linked to the volume of interventions (for example, operations) undertaken. In Australia there is, for example, evidence showing volume-outcome benefits for individual colorectal surgeons when undertaking difficult rectal surgery, though this difference is not apparent for less difficult surgery [34].

**Medical oncology services**

The estimated number of medical oncologists per new case of cancer in 2007 varied considerably, with most states and territories (except Victoria) experiencing an apparent shortfall. The Australian Medical Workforce Advisory Committee (AMWAC) reported that, in 2001, there were 14 medical oncologists and haematological oncologists per million population in Australia. AMWAC recommended that this number be increased to 16 per million population, but did not identify the ratio for each specialty separately [57].

**Availability of chemotherapy drug agents**

Cancer treatment accounts for 6% of the health expenditure. Even drug costs, about which much is heard, are quite modest. The cost of anti-cancer drugs is only 15% of the most expensive drug group (lipid-lowering agents) and 2.7% of the total expenditure on the Pharmaceutical Benefit Scheme (PBS) [6]. Indirect costs, that is, costs other than the healthcare costs, are unmeasured and often ignored. For a devastating disease like cancer, these are generally much greater than the cost of treatment [58].

Chemotherapy is mostly delivered by intravenous administration. It is provided in a variety of hospital, as well as public- and private-sector outpatient settings throughout Australia, including many rural locations. In most settings, chemotherapy regimens are determined by medical oncologists but are administered by nursing staff, under the supervision of either a medical oncologist or an appropriately qualified physician.

In 2006, more than 300,000 Medicare claims were made for chemotherapy administration throughout Australia. The number of claims per new case of cancer varied greatly among the states and territories. The PBS Schedule is part of the wider Pharmaceutical Benefits Scheme [34] managed by the Department of Health and Ageing and administered by Medicare Australia, which provides medicines to be dispensed to patients at a government-subsidised price. To explore usage of chemotherapeutic agents, we examined data on PBS services for two selected high-cost drugs, both relatively new agents approved for defined indications on the basis of evidence from randomised controlled trials [59, 60].

1. Trastuzumab, a monoclonal antibody treatment indicated in the management of HER2-neu positive breast cancer;
2. Docetaxel, an agent indicated for the adjuvant treatment of node-positive breast cancer in combination with an anthracycline, for the treatment of locally advanced or metastatic breast cancer as second-line chemotherapy, metastatic hormone-refractory prostate cancer [60], advanced, metastatic ovarian cancer, and second-line therapy in locally advanced or metastatic non-small cell lung cancer.

The Federal Government accepted a recommendation from the Pharmaceutical Benefits Advisory committee (PBAC) to list Trastuzumab on the PBS, as of October 1, 2006, for a maximum period of 12 months. Of the 14,000 women who are diagnosed with breast cancer annually in Australia, around 2100 are expected to be treated with Trastuzumab per year. The calculated costs of the 52 weeks of treatment was estimated to be in the order of $50,000 per eligible patient, with the listing of Trastuzumab anticipated to
add $470 million to the PBS expenditure between 2006-7 and 2009-2010 [61].

Similarly, with respect to Docetaxel, extension of its use in the setting of HRPC was initially rejected by the PBAC in July 2005 because of uncertain and unacceptable cost-effectiveness. In a re-submission in November 2006, its use was approved in HRPC. On updated economic evaluation, its cost was estimated to be in the range of $15,000-$45,000 (intention-to-treat population). The likely number of patients was estimated to be less than 10,000 in Year 4. The financial cost/year to the PBS was estimated to be in the range of $30-60 million in Year 4 [62].

Radiation oncology services

There is a significant deficit in radiotherapy resources in Australia, both in staffing (radiation oncologists, medical physicists, and radiation therapists) and in equipment. Waiting lists are an obvious outcome measure of the resource shortage, and long waiting time for various cancers have been documented in Australia. Evidence for this exists in clinical settings for some tumour sites, such as post-operative head and neck cancer, small cell lung cancer, high grade cerebral gliomas [63] and cervix cancer (64), where tumour control may be adversely affected [65]. In 2001 and 2002, the Royal Australian and New Zealand College of Radiologists performed audits to specifically address waiting times for radiotherapy in Australia [66]. The results show a steady decline in the number of patients commencing treatment in a timely fashion, with approximately 40% of patients receiving curative treatment, 30% receiving palliative treatment, and 56% receiving emergency treatment starting outside of standard good practice times. The Collaboration for Cancer Outcomes Research and Evaluation (CCORE) has reported an evidence base to support a utilisation rate of 52.2%, resulting in a disparity of approximately 18% between those cancer patients who should – and those who actually do – receive radiation treatment [67]. In 2002, this represented approximately 15,000 patients in Australia who could have potentially benefited from treatment, but were unable to access radiotherapy services.

LIMITATIONS OF CURRENT CANCER CARE PRACTICE IN AUSTRALIA

Optimizing Cancer Care in Australia is a consultative report prepared in 2003 by the Clinical Oncological Society of Australia, The Cancer Council Australia and the National Cancer Control Initiative, outlining key reforms required to ensure optimal treatment for cancer patients [2]. It identifies three key areas where the “health system” has failed to provide optimal care for cancer patients. These key areas are: models of cancer care, quality of cancer care, and resource issues in cancer care.

Models of cancer care

Traditional versus integrated multidisciplinary care (IMDC)

Medicare and the private health insurance system cater for the traditional model of care where the general practitioner (GP) refers a patient to a specialist (usually a surgeon) who conducts the primary intervention, usually the removal of a tumour. Patients may then see other cancer specialists sequentially for opinions before (but more often after) the primary intervention. This traditional model is criticised for its dependence upon the primary specialist reaching a conclusion that further referral is necessary. They perceive too great a risk of suboptimal therapy unless there is a more formalised method of accessing ‘integrated multidisciplinary care’ (IMDC). Much work has been invested in developing and implementing this concept and model of care. This work has been summarised in reports issued by the National Breast and Ovarian Cancer Centre [39], and includes the management of colorectal cancer [33, 34], breast [38, 39], lung [25, 26] and other malignancies such as melanoma [18].

Quality of cancer care

Improving quality of cancer care

Several major initiatives are underway in Australia which seek to assess mechanisms to improve quality in cancer care. What is striking about these initiatives is that there are relatively so few of them, especially for cancers other than breast cancer. Other drivers for quality could include the Medicare Benefits Schedule (MBS) [68]. The schedule may need to change to promote quality care. Consideration needs to be given to reviewing the MBS items with a view to promoting higher quality cancer care [69].

Improving quality through information and research

There are many gaps in our knowledge of the cancer care process, such as how advanced the disease is at diagnosis, how people are treated, as well as how treatment and potential complications affect their quality of life. Researching these issues is vital to our ability to provide optimal care. Funding for this type of research is relatively limited, but it is needed to engage in a dialogue between cancer clinicians and healthcare policy makers to help ensure services are both meeting the needs and are cost-effective.

Quality of healthcare providers

- Lack of standards in training curricula and a focus on process instead of the education system’s capacity to deliver positive healthcare outcomes.
- No credentialing of individual practitioners nor accreditation of healthcare services.
Resource issues in cancer care

Work force (shortages, roles, training, communication skills)

The cancer care workforce faces shortages in almost every category. There are shortages of specialised cancer nurses, radiation therapists, medical physicists, pharmacists and all cancer specialist clinicians (surgical oncologists, medical oncologists and radiation oncologists). The shortages show themselves most acutely in the regional areas outside major capital cities. General practice also requires development, as cancer is increasingly being treated in the community. Communication is widely recognised as problematic, especially as Australia has a culturally and linguistically diverse background.

Access issues

An unprecedented increase in cancer incidence and prevalence has lead to marked disparities in cancer mortality and morbidity across population groups (eg poorer outcomes for indigenous, rural and remote communities) as discussed earlier. This is acutely shown in access to cancer care in rural and regional centres.

A number of key access issues affect the quality of cancer care.

(1) Access to radiotherapy units

Radiation oncology is in a period of unprecedented change due to increases in the complexity of treatment and improvements in the diagnosis and staging of cancer. Such changes include the expanding use of Magnetic Resonance Imaging (MRI), Ultrasonography, Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) scanning, and the need for image fusion, multi-leaf collimators and conformal therapy, 3D-planning, and intensity modulated radiotherapy (IMRT) – all of which will increase the demands for improved patient immobilisation [70]. The delay in funding for new technologies, due to government bodies waiting for evidence-based data to show an improved outcome, thus creates significant delays in implementation especially for radiotherapy. In the context of radiation oncology practice, creditable results may require many years of follow-up.

The Royal Australian and New Zealand College of Radiologists (RANZCR) routinely surveys waiting times. In May 2001, 44% of patients surveyed started treatment within the optimum waiting time, 30% were within acceptable times, and 26% were outside the acceptable range [66]. Australian Council on Healthcare Standards data show that the proportion waiting more than three weeks for radiotherapy has doubled between 1999 and 2001 to 20% of people. The National Strategic Plan for Radiation Oncology (Australia) identified a lack of access to radiotherapy treatment centres, creating considerably real and present hardship for many patients [71].

(2) Access to pharmaceuticals (drugs)

As outlined earlier, cancer drugs that are difficult to access fall into three categories: new drugs that are not yet approved either by Pharmaceutical Benefits Advisory Committee or the Therapeutic Goods Administration (TGA) for that indication; older drugs that have not been approved for the use that they are being applied to; or older drugs that are no longer on the Australian Register of Therapeutic Goods.

(3) Access to services including palliative care

Travelling to a treatment centre is a serious barrier to access. Substantial cost is incurred in accessing treatment and some people cannot afford it, especially for prolonged periods of radiotherapy. Greater access to home care, better access to psychological support, and support for carers and families can all decrease the impact of cancer. Although overall access to palliative care in Australia is adequate, referral to palliative care units is often too late or only during a crisis, and one third of the potential population is never referred [2]. One common problem is late referral, which is closely related to the failure to involve palliative care practitioners in care-planning at an earlier stage. Part of the solution is to educate specialists, GPs and the community about palliative care and to change its image. This is particularly pertinent for special groups such as Australian Aboriginals and those from non-English speaking backgrounds, ensuring that they know about the services and how to access it.

POTENTIAL SOLUTIONS AND FUTURE IMPROVEMENTS IN CANCER CARE AND SERVICE DELIVERY

In the 2004-5 Federal budget, almost $190 million in funding was pledged to be made available over a five-year period until 2008-9 for the ‘Strengthening Cancer Care’ initiative. Most of the states and territories in Australia have now developed their own local cancer control plans. In particular, the two most populous states, Victoria and New South Wales, have produced a ‘Cancer Services Framework for Victoria’ [72] and the NSW Cancer Plan 2004-2006, respectively [73]. This plan outlined 33 specific goals in the 10 strategic areas, covering:

- Coordination of cancer control
- Cancer prevention and early detection
- Cancer service provision – the patient’s journey
- Special issues in cancer care
- Cancer information
- Cancer education
- Cancer workforce
- Cancer research
- Cancer fundraising
- Quality, evaluation and accreditation

The strengths of these successive comprehensive national and state-based initiatives and reports, have been to identify priority cancers and strategies that have the potential to improve cancer outcomes, decrease morbidity and mortality and address inequalities in cancer care [2]. However there are several major areas of weaknesses in these initiatives. These relate to the relative lack of implementation plans, the absence of dedicated funding for implementation, too few economic analyses supporting priority actions and strategies, and little or no evaluation of the uptake or impact of cancer control plans [74]. These challenges are magnified by the fact that those responsible for producing these plans are not always the same groups who have the authority to execute and implement them, and who may have differing priorities. For example, the Cancer Institute NSW has control over a very small part of NSW’s health expenditure on cancer. This is in contrast, notably, with the British National Health Service, which has both the authority to both produce strategic plans and implement them [74]. Other weaknesses include the lack of well-structured implementation strategies and a clear assignment of responsibility and accountability mechanisms.

As outlined in the COSA report [75], cancer care in Australia is thus compounded by associated population pressures, and faces the following demographic challenges and systemic problems:

- Fragmentation of the system across multiple tiers, compromising efficiency of training, planning, recruitment and retention processes.
- Established priorities based on requirements of disparate organisations rather than on Australia’s national healthcare needs as shown by epidemiological data.
- Bureaucratisation and politicisation of government-funded health services.
- No national framework to facilitate staff movement or re-entry across the system.
- No infrastructure for ushering in, and adapting, to rapid technological change.
- No national, independent approach to data collection and use.

Optimising Cancer Care

The Optimising Cancer Care in Australia (OCCA) report proposed 12 key recommendations and 19 actions items. These related to the key areas of change: models of cancer care, quality of cancer care, resources issues in care and improving the delivery of cancer care [2]. The recommendations emphasised integrated multidisciplinary care, care throughout the cancer journey, including palliative and supportive care, and improved consumer access to information. There were also recommendations for the development of an accreditation system for cancer services, improved access to clinical trials, psycho-oncology services and to new and accepted drugs, implementation of already existing workforce plans for the oncology workforce and for radiation oncology, revision of the system of support for the travel of patients and carers to receive care, and special attention to equity of access, especially for indigenous Aboriginal people. The recommendations were intended for consideration by the Commonwealth Minister for Health and Ageing in concert with state and territory health authorities.

Strengthening Cancer Care

“Strengthening Cancer Care” was released prior to the federal election in 2004 by the former Coalition government [76]. This document outlined a series of initiatives to improve cancer care in Australia, including supporting Australians living with cancer and the professionals who care for them, enhancing screening and prevention efforts in bowel and skin cancer, prevention of smoking in pregnancy, better access to Pap smears for cervical cancer, ensuring better coordination for national cancer efforts, and more research funding dedicated to cancer and cancer care. Funding of almost $190 million for these cancer care initiatives in the five years to 2008-2009 had been approved. State cancer plans now exist for each mainland state in Australia. The Northern Territory has recently commissioned a group to develop its cancer plan. These plans cover the spectrum of cancer control activity from prevention and screening to palliation and rehabilitation. They provide a framework for benchmarking services and for prioritising funding initiatives.

FUTURE VISION AND DIRECTIONS OF CANCER CARE IN AUSTRALIA

Cancer outcomes in Australia are among the best in the world but there remains significant morbidity, mortality and expenses involved. The major issues for Australia are quality of service, distribution and access to services and the increasing cost of drugs and technology. Strategies to improve the quality of service include accreditation of training institutions, credentialing of practitioners and improvements in information technology. Accreditation and credentialing recognise the contribution of expertise to better outcomes. The current debate surrounds the best method to enforce accreditation and the content of the standards that will be used, such as that outlined and suggested in the ‘Cancer Services Framework for Victoria’ report [72]. Meaningful standards will also require significantly better information management. Currently only incidence, mortality and survival data are routinely collected and reported. Staging and treatment data are only available from a limited number of hospital-based registries such as those in South Australia. There are also initiatives to develop and assess cancer multi-
disciplinary teams with more objective criteria and performance benchmarks [77].

Australia has an extremely dispersed geographic population. One-third of the population lives outside major metropolitan centres. Recent initiatives have sought to improve the provision of services in rural and regional areas with the opening of new cancer centres in many major country towns in Victoria and NSW. There is no radiotherapy service in Darwin, the capital of the Northern Territory, and cancer patients have to travel a minimum of four hours (by flight) to the nearest service. Providing services in isolated centres means it is more expensive because a minimum of two linear accelerators are required to prevent interruptions to treatment by equipment breakdowns. Staffing may be difficult because of the overall shortages of skilled staff, particularly at a senior level. Establishment of cancer networks, linking metropolitan areas with more regional and remote areas, in terms of staff, training, and sharing of other resources facilitated by appropriate information and communication technologies (ICT) may be one of the potential solutions to the challenges burgeoning cancer care in an ageing population. The high cost of new biological agents, as well as new imaging and treatment technology presents a major challenge to health services that are already short of funding. Technological innovations such as IMRT may prolong treatment duration and reduce patient throughput and thus decrease treatment capacity. Technological innovation is often introduced without evidence of benefit and safety that would be required for new drugs.

In summary, cancer care in Australia, as measured by selected outcomes, are among the best in the world; however there continues to be evidence of health inequalities especially among patients residing in regional and remote areas, the indigenous population and those of lower socio-economic classes. Ongoing implementation of the many national and state cancer control plans and evaluation of their effectiveness will be needed to pursue the goal of optimal cancer care.

REFERENCES

1. Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality Books [Online]. 2004; Available at http://www.aihw.gov.au/cancer/data/acim_books/index.cfm. (Accessed 26 February 2008).
2. The Cancer Council Australia, The National Cancer Control Initiative, Clinical Oncological Society of Australia. Optimising Cancer Care. Melbourne: National Cancer Control Initiative, 2003.
3. Ferlay J, Bray F, Pisani P et al: GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. Lyon, France: IARC Press, 2004.
4. Australian Institute of Health and Welfare. Australian's Health 2004. Canberra: 2006.
5. Medicare Australia. The Australian Government 2008 [Online]. Available at http://www.medicareaustralia.gov.au/public/register/index.shtml. (Accessed 15 March 2008).
6. Department of Health and Ageing. Schedule of Pharmaceutical Benefits. Canberra: National Capital Printing, 2006.
7. Commonwealth Department of Human Services and Health. Better health outcomes for Australians. National goals, targets and strategies for better health outcomes into the next century. Canberra: 1994.
8. MacLennan R. Vol. 1. Australia Cancer Society, 1987.
9. Australian Cancer Society. National Cancer Prevention Policy 1993. Woolloomooloo NSW: 1993.
10. The Cancer Council Australia. National Cancer Prevention Policy 2001-3. Melbourne: 2001.
11. National Cancer Control Initiative. Cancer control towards 2002 - the first stage of a nationally coordinated plan for cancer control. Canberra, 1998; Volume 2428.
12. National Health Priority Action Council (NHPAC). National Service Improvement Framework for Cancer. Canberra: 2005.
13. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63(1):38-18.
14. Marks R. Two decades of the public health approach to skin cancer control in Australia: why, how and where are we now? Australas J Dermatol 1999; 40(1):1-5.
15. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365(9460):687-701.
16. Gilchrest BA, Eller MS, Geller AC et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340(17):1341-8.
17. Houghton AN, Coit DG, Daud A et al. Melanoma. J Natl Compr Canc Netw 2006; 4(7):666-84.
18. NH & MRC. Clinical Practice Guidelines: The Management of Cutaneous Melanoma. Canberra: 1999.
19. The National Cancer Control Initiative. The 2002 national melanoma skin cancer survey. Melbourne: The National Cancer Control Initiative, 2003.
20. Thompson JF, Shaw HM, Stretch JR et al. The Sydney Melanoma Unit--a multidisciplinary melanoma treatment center. Surg Clin North Am 2003; 83(2):431-51.
21. Thompson JF, Uren RF. Lymphatic mapping in management of patients with primary cutaneous melanoma. Lancet Oncol 2005; 6(11):877-85.
22. Thompson JF, Scolyer RA, Uren RF. Surgical management of primary cutaneous melanoma: excision margins and the role of sentinel lymph node examination. Surg Oncol Clin N Am 2006; 15(2):301-18.
23. Thompson JF, Shaw HM. Sentinel node mapping for melanoma: results of trials and current applications, Surg Oncol Clin N Am 2007; 16(1):35-54.
24. Elliott B, Scolyer RA, Suciu S et al. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res 2007; 13(13):3825-30.
25. NH & MRC. Clinical Practice Guidelines for the prevention, diagnosis and management of lung cancer. Sydney: The Cancer Council Australia, 2004.
26. Conron M, Phuah S, Steinfort D et al. Analysis of multidisciplinary lung cancer practice. Intern Med J 2007; 37(1):18-25.
27. Vinod SK, Hui AC, Esmaili N et al. Comparison of patterns of care in lung cancer in three area health services in New South Wales, Australia. Intern Med J 2004; 34(12):677-83.
28. Holloway L. Current practice when treating lung cancer in Australasia. Australas Radiol 2007; 51(1):62-7.
29. Commonwealth of Australia. National Drug Strategy [Online]. Available at http://www.nationaldrugstrategy.gov.au.
30. Australian Government Department of Health and Aged Care and the Ministerial Council on Drug Strategy (MCDS). National Tobacco Strategy 2004-2009. Canberra: Australian Government, Department of Health and Aged Care, 2005.
31. World Health Organization. WHO Framework Convention on Tobacco Control (WHO FCTC) [Online]. Available at http://www.who.int/tobacco/framework/en/.
32. Department of Health and Ageing. National Bowel Screening Program. 2007.
33. NH & MRC. Guidelines for the prevention, early detection and management of colorectal cancer: A guide for general practitioners. 2000.
34. NH & MRC. Guidelines for the prevention, early detection and management of colorectal cancer. 2005.
35. Young JM, Leong DC, Armstrong K et al. Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study. Med J Aust 2007; 186(6):292-5.
36. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients
treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2002. 2008; CD002200.

37. National Breast and Ovarian Cancer Centre. NBOCC Breast Health statistics, 2002 [Online]. 2008; Available at http://www.nbocc.org.au/. (Accessed 15 March 2008).

38. National Breast and Ovarian Cancer Centre N&M. Clinical Practice Guidelines for the Management of Early Breast Cancer. 2nd edition. Canberra: 2001.

39. National Breast and Ovarian Cancer Centre (NBOCC). Multidisciplinary Care [Online]. 2008; Available at http://www.nbocc.org.au. (Accessed 2 March 2008).

40. BreastScreen Australia Program. Australian Government Department of Health and Ageing [Online]. 2008; Available at http://www.breastscreen.info.au/internet/screening/publishing.nsf/Content/breastscreen-lhp. (Accessed 15 March 2008).

41. Australian Institute of Health and Welfare, National Breast Cancer Centre. Breast Cancer in Australia, an Overview, 2006. Canberra: AIHW; CAN29. (Cancer series; 34).

42. National Health & Medical Research Council. Guidelines for the Prevention, Early Detection and Management of Prostate Cancer. 2002.

43. American Urological Association. Guideline for the Management of Clinically Localised Prostate cancer - 2007 update. 2007.

44. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15):1502-12.

45. Baade PD, Fritschi L, Aitken JF. Geographical differentials in cancer incidence and survival in Queensland: 1996-2002. Brisbane: 2005.

46. Condon J. Cancer, health services and Indigenous Australians. Aboriginal and Torres Strait Islander Primary Health Care Review. Canberra: Office for Aboriginal and Torres Strait Islander Health, 2004; Consultant Report no. 5.

47. Roder ID. Comparative cancer incidence, mortality and survival in Indigenous people in Australia. Cancer Forum 2005; 29(1):7-9.

48. South Australian Cancer Registry. Epidemiology of cancer in South Australia. Adelaide: South Australian Cancer Registry, 1997.

49. Valery PC, Coory M, Stirling J et al. Cancer diagnosis, treatment, and survival in Indigenous and non-Indigenous Australians: a matched cohort study. Lancet 2006; 367(9525):1842-8.

50. Australian Bureau of Statistics. Australian social trends. Canberra, Australia: 2003.

51. Australian Institute of Health and Welfare, Australian Association of Cancer Registrars. Cancer survival in Australia 1992-1997. Geographic categories and socioeconomic status. Canberra: AIHW, 2003; CAN17. (Cancer Series; 22).

52. Jong KE, Smith DP, Yu XQ et al. Remote provision of breast cancer care in New South Wales. Med J Aust 2004; 180(12):618-22.

53. Australian Institute of Health and Welfare, Australasian Association of Cancer Registrars. Cancer in Australia 2001. 2004 Dec.

54. McCredie M, Bell J, Lee A et al. Differences in patterns of care of prostate cancer, New South Wales, 1991. Aust N Z J Surg 1996; 66(11):727-30.

55. Kricker A, Haskill J, Armstrong BK. Breast conservation, mastectomy and axillary surgery in New South Wales women in 1992 and 1995. Br J Cancer 2001; 85(5):668-73.

56. Armstrong K, O'Connell D, Leong D et al. The NSW Colorectal Cancer Care Survey 2000. New South Wales: The Cancer Council NSW, 2004.

57. Australian Medical Workforce Advisory Committee. The specialist medical and haematological oncology workforce in Australia. Sydney: AMWAC, 2001.

58. Access Economics, NSW Cancer Council. Cost of Cancer in NSW. Wolloomooloo: NSW Cancer Council, 2007.

59. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369(9555):29-36.

60. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2):242-5.

61. Department of Health and Ageing. Listing of Herceptin on the PBS. Canberra: 2006.

62. Department of Health and Ageing. Listing of Docetaxel on the PBS. Canberra: 2006.

63. Do V, Gerecke V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol 2000; 57(2):131-6.

64. Coles CE, Burgess L, Tan LT. An audit of delays before and during radical radiotherapy for cervical cancer—effect on tumour cure probability. Clin Oncol (R Coll Radiol) 2003; 15(2):47-54.

65. Seel M, Foroudi F. Waiting for radiation therapy: does it matter? Australas Radiol 2002; 46(3):275-9.

66. Kenny L, Lehman M. Sequential audits of unacceptable delays in radiation therapy in Australia and New Zealand. Australas Radiol 2004; 48(1):29-34.

67. Delaney G, Jacob S, Featherstone C et al. The role of radiotherapy in cancer treatment: estimating potential utilisation from a review of evidence-based clinical guidelines. Cancer 2005; 104(6):1129-37.

68. Australian Government. Medicare Australia [Online]. 2008; Available at http://www.medicareaustralia.gov.au/provider/medicare/mbs.shtml. (Accessed 15 March 2008).

69. Victorian Government. Clinical excellence in cancer care - a model for safety and quality in Victorian cancer services. Melbourne: Metropolitan Health and Aged Care services, 2007.

70. Lee N, Puri DR, Blanco AI et al. Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck 2007; 29(4):387-400.

71. National Radiation Oncology Strategic Plan Steering Committee (NROPSC). National Strategic Plan for Radiation Oncology (Australia). Sydney: 2008.

72. The Collaboration for Cancer Outcomes Research and Evaluation. A Cancer Services Framework for Victoria and future directions for the Peter MacCallum Cancer Institute. Melbourne: 2003.

73. Cancer Institute NSW. NSW Cancer Plan 2004-2006. Sydney: Cancer Institute NSW, 2001.

74. Reis AJ. New surgical approach for late complications from spinal cord injury. BMC Surg 2006; 6:12.

75. Clinical Oncological Society of Australia, The Cancer Council Australia. Submission to the Productivity Commission study of Australia’s health workforce. 2006: 1-22.

76. Commonwealth Department of Health and Ageing. Strengthening Cancer Care. Canberra: 2004.

77. NSW Cancer Institute. Multidisciplinary Teams [Online]. 2008; Available at http://www.cancerinstitute.org.au/cancer_inst/profes/mdt.html. (Accessed 10 March 2008).

78. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54(1):8-29.

79. de Vries E, Schouten LJ, Visser O et al. Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient? Eur J Cancer 2003; 39(10):1439-46.

80. Cancer Research UK. Cancer Research UK Statistics: cancer statistics reports [Online]. 2008; Available at http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstats report. (Accessed 15 March 2008).

81. Threlfall T, Bramfield K. Cancer survival in Australia for cancer residents, 1982-1997. Perth: Health Department of Western Australia, 2000.

82. Supramaniam R, Smith D, Coates M et al. Survival from cancer in New South Wales in 1980 to 1995. Sydney: 1999.

83. Berrino F, Capocaccia R, Esteve J. Survival of cancer patients in Europe: the Eurocare-2 study. Lyon: IARC, 1999.

84. Baade P, Coory M, Ring I. Cancer survival in Queensland 1982-1995. Brisbane: Health Information Centre, 2000.